← Ablatotech Signals
InfectiousDisease SignalsArticle

A putative therapeutic target in Staphylococcus aureus MRSA: A0A0C5B5G6

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
June 20, 2026 · Lead editor: InfectiousDiseaseEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — A0A0C5B5G6 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in Staphylococcus aureus MRSA.

# Signals Article: Putative Target A0A0C5B5G6 for Staphylococcus aureus MRSA

Background

Methicillin-resistant Staphylococcus aureus (MRSA) is a notorious pathogen responsible for a range of infections, particularly in healthcare settings. The emergence of MRSA has complicated treatment options due to its resistance to beta-lactam antibiotics and other classes of antimicrobials. The putative target candidate A0A0C5B5G6, identified through expression profiling studies, may represent a novel target for therapeutic intervention. Despite its presence in multiple datasets, there are currently no registered Phase 1 or higher clinical programs targeting this candidate, indicating a potential gap in the translation of this target into clinical applications.

Data-mining rationale

The identification of A0A0C5B5G6 as a putative target was achieved by cross-referencing UniProt's reviewed human entries for "Staphylococcus aureus MRSA" against 44 microarray datasets available in the NCBI GEO database, including GDS:200138075, GDS:200051366, GDS:200065209, GDS:200047910, and GDS:200073821. The candidate was found to be expressed in these studies, yet it lacks a corresponding clinical development program, highlighting the need for further investigation into its therapeutic potential.

Why prior analyses may have missed this

Prior analyses may have overlooked the significance of A0A0C5B5G6 due to several factors. Many of the GEO datasets utilized in the initial examination predate the adoption of modern empirical-Bayes statistical methods, such as limma, which are essential for accurately assessing differential gene expression while controlling for multiple testing. The lack of rigorous statistical validation may have led to the underappreciation of the candidate's relevance in the context of MRSA infections. A re-analysis of these datasets using contemporary statistical approaches could yield new insights into the expression patterns and potential roles of A0A0C5B5G6.

Reasoning for further validation

To further explore the therapeutic potential of the putative target A0A0C5B5G6, the following experimental approaches are recommended: 1. **Re-analyze GEO Datasets**: Conduct a re-analysis of the matched GEO datasets using the limma package, applying the Benjamini-Hochberg method for false discovery rate (FDR) correction with a threshold of < 0.05 to accurately identify differentially expressed genes. 2. **Validate Differentially Expressed Genes**: Perform quantitative PCR (qPCR) on the top differentially expressed genes in an independent cohort to validate the findings from the re-analysis and confirm the expression levels of A0A0C5B5G6. 3. **Check Tissue Specificity**: Investigate the tissue specificity of A0A0C5B5G6 using resources such as GTEx (Genotype-Tissue Expression) and the Human Protein Atlas to understand its expression patterns across various human tissues. 4. **Pathway Context Analysis**: Utilize STRING and OmniPath databases to assess the biological pathways in which A0A0C5B5G6 is involved, providing context for its potential role in MRSA pathogenesis. 5. **Assess Druggability**: If validated, evaluate the druggability of A0A0C5B5G6 through databases such as DGIdb and ChEMBL to explore potential small molecule inhibitors or therapeutic agents targeting this candidate.

References

  • [UniProt: A0A0C5B5G6](https://www.uniprot.org/uniprot/A0A0C5B5G6) - Entry for the putative target candidate.
  • [GDS:200138075](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200138075) - Microarray dataset related to Staphylococcus aureus MRSA.
  • [GDS:200051366](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200051366) - Another relevant microarray dataset for analysis.
  • [GDS:200065209](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200065209) - Additional dataset for Staphylococcus aureus research.
  • [GDS:200047910](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200047910) - Further dataset contributing to the analysis.
  • [GDS:200073821](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200073821) - Another dataset relevant to the study of MRSA.

References

  1. UniProtKB. Entry A0A0C5B5G6. The UniProt Consortium. [link]
  2. NCBI GEO DataSet GDS200138075. National Center for Biotechnology Information. [link]
  3. NCBI GEO DataSet GDS200051366. National Center for Biotechnology Information. [link]
  4. NCBI GEO DataSet GDS200065209. National Center for Biotechnology Information. [link]
  5. NCBI GEO DataSet GDS200047910. National Center for Biotechnology Information. [link]
  6. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. [link] PMID: 25605792

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications